We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+16.05%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.4B
AUM Growth
-$622M
Cap. Flow
-$2.95B
Cap. Flow %
-25.85%
Top 10 Hldgs %
75.13%
Holding
138
New
10
Increased
24
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.13B
2
ABBV icon
AbbVie
ABBV
+$938M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$82.3M
4
ATYR
aTyr Pharma
ATYR
+$51.8M
5
DYAX
DYAX CORPORATION
DYAX
+$50.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$2.31B
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.14B
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$38M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 77.51%
2 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.9B
$1.55B 13.59%
14,865,559
+20,000
+0.1% +$2.07M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$1.49B 13.11%
30,870,262
+1,993,550
+7% +$82.3M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$1.18B 10.37%
+6,542,599
New +$1.13B
ABBV icon
4
AbbVie
ABBV
$468B
$966M 8.47%
+14,373,538
New +$938M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$5.08B
$858M 7.52%
20,481,442
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12.9B
$560M 4.91%
4,095,247
-105,209
-3% -$13M
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$380M 3.33%
13,657,598
+656
+0% +$18.5K
ANAC
8
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$281M 2.46%
3,625,498
-579,204
-14% -$38M
DYAX
9
DELISTED
DYAX CORPORATION
DYAX
$210M 1.84%
7,926,630
+1,905,145
+32% +$50.5M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.44B
$173M 1.52%
11,577,299
+1,099,095
+10% +$12.5M
NVTA
11
DELISTED
Invitae Corporation
NVTA
$97.5M 0.86%
6,554,967
– –
BLCM
12
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$89.1M 0.78%
419,059
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$88.3M 0.77%
2,805,074
– –
HRTX icon
14
Heron Therapeutics
HRTX
$60.4M
$87.5M 0.77%
2,807,784
+200,000
+8% +$3.76M
ONCE
15
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$76.1M 0.67%
1,262,382
-65,069
-5% -$4.3M
CERS icon
16
Cerus
CERS
$566M
$70.3M 0.62%
13,553,275
– –
XOMA
17
DELISTED
Xoma
XOMA
$57M 0.5%
734,176
-1,255
-0.2% -$90.4K
DBVT
18
DBV Technologies
DBVT
$914M
$55.5M 0.49%
186,202
+34,279
+23% +$8.86M
ARAV
19
DELISTED
Aravive, Inc. Common Stock
ARAV
$52.3M 0.46%
572,764
+76,531
+15% +$7.75M
ALDR
20
DELISTED
Alder Biopharmaceuticals
ALDR
$47.2M 0.41%
891,688
+12,107
+1% +$440K
HALO icon
21
Halozyme
HALO
$12.3B
$43.6M 0.38%
1,931,057
-317,095
-14% -$5.57M
ATYR
22
aTyr Pharma
ATYR
$49.2M
$43.2M 0.38%
+166,795
New +$51.8M
XNPT
23
DELISTED
XENOPORT, INC.
XNPT
$39.9M 0.35%
6,508,622
– –
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
$39.5M 0.35%
5,482,505
-176,250
-3% -$1.3M
INSM icon
25
Insmed
INSM
$27.5B
$38.7M 0.34%
1,583,490
– –
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2015 Portfolio in Review

As of Q2 2015, Julian Baker held 138 positions worth $11.4B, down 5.2% from $12B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Julian Baker withdrew a net $2.95B in Q2 2015, closing 12 positions and reducing 17 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $2.31B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 46% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in Alexion Pharmaceuticals worth $1.18B.

  • Julian Baker's largest Q2 2015 buy was Alexion Pharmaceuticals: 6,542,599 shares worth $1.18B.
  • Julian Baker added most to Seagen Inc. Common Stock in Q2 2015, an estimated $82.3M increase.
  • Julian Baker's biggest Q2 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $38M.
  • Julian Baker fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.31B.
  • Julian Baker's ten largest holdings make up 75% of its $11.4B portfolio in Q2 2015.
  • Julian Baker opened 10 new positions and closed 12 in Q2 2015.
  • Julian Baker's portfolio value fell 5.2% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.